We have partnered with collaborators to securely share our scientific data for more than 15 years. It is through these efforts that we have been able to carefully advance our collective understanding of human genomic variation and inherited disease, and responsibly apply genetic technologies in the era of genomics.
|2017 Genitourinary Cancers Symposium
Thursday, February 16th –Saturday, February 18th
|Thursday, February 16th, 11:30am-1:00pm & 5:15-6:15pm
Poster #D20, Abstract #85
Bowling L, et al. Gender disparity: Overlooking hereditary prostate cancer
|Saturday, February 18th, 11:30am-1:00pm & 7:00-7:55pm
Poster #F5, Abstract #490
Horton C, et al. BAP1 tumor predisposition syndrome: Preliminary data from a laboratory-based multi-gene panel testing cohort
|2017 SGO Annual Meeting on Women’s Cancer
Monday, March 13, 3:30-5:00pm & Tuesday, March 14, 3:30-4:30pm
Frey MK, et al. Prospective evaluation of facilitated referral pathway to improve uptake of genetic assessment for women with newly diagnosed ovarian cancer
Namey T, et al. Frequency of germline mutations in BRIP1, RAD51C, and RAD51D among women with ovarian, primary peritoneal, and Fallopian tube cancer
Horton C, et al. In laboratory clinical data we trust? Accuracy and completeness of test requisition form data in a cohort of ovarian and uterine cancer patients referred for clinical genetic testing
|2017 Society of Surgical Oncology
Wednesday, March 15th-Saturday, March 18th
|34th Annual Miami Breast Cancer Conference
Thursday, March 9th – Sunday, March 12th
|Paudyal T, et al. Multigene panel ordering preferences for breast cancer patients: A comparison across physician specialties|
|2017 ACMG Annual Clinical Genetics Meeting|
Thursday, March 23rd, 2017Presentations:
Scientific Concurrent Sessions:
|Mayo Clinic Partners with Ambry in Largest Hereditary Breast Cancer Patient Study to Date|
|Fergus Couch, et al. Ambry authors: Robina Smith, Melissa Pronold, Robert Huether, Carin Espenschied, Shuwei Li, Tina Pesaran, Rachel McFarland, Holly LaDuca, Jill Dolinsky|
|Quick Take: Mayo Clinic and University of Utah researchers collaborated with Ambry Genetics to study more than 60,000 women diagnosed with breast cancer over a four-year period, with >90% of them meeting National Comprehensive Cancer Network (NCCN®) hereditary breast ovarian cancer (HBOC) testing criteria. All had germline testing using multi-gene panels performed at Ambry. This represents the largest genetic study to date of women with breast cancer, and offers new information about genes that may or may not contribute to breast cancer risk.|
Stay in the Gnome is our quarterly collection of our internal and collaborative scientific work. It is organized by quarter below, with clickable links to full publications
(when possible), abstracts, and posters.
Click here to view all of our peer-reviewed publications, organized by general topic/product line.
For questions about clinical research or collaborations at Ambry, please fill out the form found here and select "Answer a Question about Research and Collaboration Services."